FindTrial
Sign In

Prevalence of two mutations (KRAS and BRAF) in patients diagnosed with Colorectal Cancer.

Prevalence of KRAS and BRAF mutations in subjects diagnosed with Colorectal Cancer- a prospective, single center study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2013/09/004023
Enrollment
200
Registered
2013-09-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Colorectal cancer

Interventions

None listed

Sponsors

Dr Prachi S Patil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: •Subjects with age above 18 years •Subjects with histologically confirmed adenocarcinoma of the colon or rectum •Subjects who have not received any prior systemic therapy for CRC

Exclusion criteria

Exclusion criteria: Subjects with previous systemic therapy for CRC

Design outcomes

Primary

MeasureTime frame
Prevalence of KRAS mutation in subjects with CRC.Timepoint: 12 months—

Secondary

MeasureTime frame
Prevalence of KRAS mutation in subjects with CRC.Timepoint: 12 months—

Countries

India

Contacts

Public ContactDr Prachi S Patil

Tata Memorial Hospital

prachipatil@gmail.com91-22-24177205

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026